Oramed Pharmaceuticals (ORMP) Other Accumulated Expenses (2021 - 2026)

Oramed Pharmaceuticals (ORMP) has 6 years of Other Accumulated Expenses data on file, last reported at $285000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $285000.0 (changed N/A YoY) and the FY2025 annual result came in at $633000.0, up 87.28% from the prior year.
• Other Accumulated Expenses declined to $285000.0 in Q1 2026, from $633000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $633000.0 in Q4 2025 to a low of $5000.0 in Q4 2022.
• A 5-year average of $175083.3 and a median of $114500.0 in 2022 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 1080.0% in 2023, down 55.64% in 2023.
• Tracing ORMP's Other Accumulated Expenses over 5 years: stood at $5000.0 in 2022, then surged by 1080.0% to $59000.0 in 2023, then jumped by 472.88% to $338000.0 in 2024, then surged by 87.28% to $633000.0 in 2025, then plunged by 54.98% to $285000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $285000.0 (Q1 2026), $633000.0 (Q4 2025), and $338000.0 (Q4 2024), per Business Quant data.